RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - Modulazione farmacologica della chemioterapia antitumorale
• 2 - La cardiotossicità da terapia anti-neoplastica coinvolge le cellule staminali e progenitori miocardici residenti
• 3 - Ruolo fisiopatologico di poli(ADPR)polimerasi (PARP) e sue implicazioni terapeutiche.
• 4 - RNA come target molecolare di nuovi farmaci antitumorali
• 5 - Sviluppo e progressione del carcinoma epatocellulare: meccanismi molecolari ed implicazioni terapeutiche
• 6 - Studio delle alterazioni biomolecolari e dei profili di espressione genica nel carcinoma colorettale e pancreatico: identificazione di possibili elementi prognostici e bersagli terapeutici nel sistema degli eicosanoidi e dei cannabinoidi.
• 7 - Vie di trasduzione e modifiche traduzionali e post-traduzionali nella protezione dall'apoptosi: disegno di nuove strategie terapeutiche antitumorali.
• 8 - RUOLO DELLA FARMACOGENETICA NELLA DEFINIZIONE DELL'ATTIVITA' E TOLLERABILITA' DELLA CHEMIOTERAPIA ANTINEOPLASTICA
• 9 - Studio delle basi molecolari e cellulari della risposta alla terapia mirata con inibitori delle tirosin-kinasi per l'ottimizzazione del trattamento delle leucemia Philadelphia positive
• 10 - Basi razionali per lo sviluppo di protocolli di polichemioterapia finalizzati al superamento della chemioresistenza tumorale

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze biologiche
  • BIOCHIMICA
  • FARMACOLOGIA
• Area scientifico disciplinare: Scienze mediche
  • PATOLOGIA GENERALE
  • ONCOLOGIA MEDICA

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF (biocides, pest repellants or attractants, or plant growth regulators, containing micro-organisms, viruses, microbial fungi, enzymes, fermentates or substances produced by or extracted from micro-organisms or animal material A01N63/00; food compositions A21, A23; medicinal preparations A61K; chemical aspects of, or use of materials for, bandages, dressings, absorbent pads or surgical articles A61L; fertilisers C05); PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS (preservation of living parts of humans or animals A01N1/02); MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (micro-biological testing media C12Q)
• HUMAN NECESSITIES
  • MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (bringing into special physical form A61J [N: mechanical aspects]; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; compounds per se C01, C07, C08, C12N; soap compositions C11D; micro-organisms per se C12N) [C0203]

Classificazione geografica

• Regione: Abruzzo

Bibliografia

1. Weiss RB (1992) The anthracyclines : will we ever find a better doxorubicin ? Sem Oncol 19: 670-686.

2. Ryberg M, Nielsen D, Skovsgaard T, Hansen J, Jensen BV and Dombernowsky P (1998) Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol 16: 3502-3508.

3. Anderlini P, Benjamin RS, Wong FC, Kantarjian HM, Andreeff M, Kornblau SM, O'Brien S, Mackay B, Ewer MS and Pierce SA (1995) Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol 13: 2827-2834.

4. Thomas X, Le QH and Fiere D (2002) Anthracycline-related toxicity requiring cardiac transplantation in long-term disease-free survivors with acute promyelocytic leukaemia. Ann Hematol 81: 504-507

5. Drummond DC, Meyer O, Hong K, Kirpotin DB and Papahadjopoulos (1999) Optimizing Liposomes for Delivery of Chemotherapeutic Agents to Solid Tumors. Pharmacol Rev 51: 692-743.

6. Gibbs DD, Pyle L, Allen M, Vaughan M, Webb A, Johnston SR and Gore ME (2002) A phase I dose-finding study of a combination of pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancer. Br J Cancer 86: 1379-1384.

7. Gianni L, Dombernowsky P, Sledge G, Martin M, Amadori D, Arbuck SG, Ravdin P, Brown M, Messina M, Tuck D, Weil C and Winograd B (2001) Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancer. Ann Oncol 12: 1067-1073.

8. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, Murphy M, Stewart SJ and Keefe D (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20: 1215-1221.

9. Dowd NP, Scully M, Adderley SR, Cunningham AJ and Fitzgerald DJ (2001) Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo.J Clin Invest 108: 585-590.

10. Patel VA, Dunn MJ, and Sorokin A (2002) Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. J Biol Chem 277: 38915-38920.

11. Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57: 727–741.

12. Taatjes DJ and Koch TH (2001) Nuclear targeting and retention of anthracycline antitumor drugs in sensitive and resistant tumor cells. Curr Med Chem 8 : 15-29.

13. Kim R, Tanabe K, Uchida Y, Emi M, Inoue H and Toge T (2002) Current status of the molecular mechanisms of anticancer drug-induced apoptosis. The contribution of molecular-level analysis to cancer chemotherapy. Cancer ChemotherPharmacol 50: 343-352.

14. Laurent G and Jaffrezou JP (2001) Signaling pathways activated by daunorubicin. Blood 98: 913-924.

15. Binaschi M, Bigioni M, Cipollone A, Rossi C, Goso C, Maggi CA, Capranico G and Animati F (2001) Anthracyclines: selected new developments. Curr Med Chem 1:113-130.

16. Kiyomiya K, Kurebe M, Nakagawa H and Matsuo S (2002) The role of the proteasome in apoptosis induced by anthracycline anticancer agents. Int J Oncol 20: 1205-1209.

17. Olson RD and Mushlin PS (1990) Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J. 4: 3076-3086.

18. Jeyaseelan R, Poizat C, Wu HY and Kedes L (1997) Molecular mechanisms of doxorubicin-induced cardiomyopathy : Selective suppression of Reiske iron–sulfur protein, ADP/ATP translocase, and phosphofructokinase genes is associated with ATP depletion in rat cardiomyocytes. J Biol Chem 272: 5828-5832.

19. Yamaoka M, Yamaguchi S, Suzuki T, Okuyama M, Nitobe J, Nakamura N, Mitsui Y and Tomoike H (2000) Apoptosis in rat cardiac myocytes induced by Fas ligand: priming for Fas-mediated apoptosis with doxorubicin. J Mol Cell Cardiol 32: 881-889.

20. Kalyanaraman B, Joseph J, Kalivendi S, Wang S, Konorev E and Kotamraju S (2002) Doxorubicin-induced apoptosis: Implications in cardiotoxicity Mol Cell Biochem 234/235: 119–124.

21. Tokarska-Schlattner M, Wallimann T and Schlattner U (2002) Multiple interference of anthracyclines with mitochondrial creatine kinases: Preferential damage of the cardiac isoenzyme and its implications for drug cardiotoxicity. Mol Pharmacol 61: 516-523.

22. Kim Y, Ma AG, Kitta K, Fitch SN, Ikeda T, Ihara Y, Simon AR, Evans T and Suzuki YJ (2003) Anthracycline-induced suppression of GATA-4 transcription factor: implication in the regulation of cardiac myocyte apoptosis. Mol. Pharmacol. 63: 368-377.

23. Kitta K, Day RM, Kim Y, Torregroza I, Evans T and Suzuki YJ (2003) Hepatocyte growth factor induces GATA-4 phosphorylation and cell survival in cardiac muscle cells. J Biol Chem 278: 4705-4712.

24. Pacher P, Liaudet L, Bai P, Mabley JG, Kaminski PM, Virag L, Deb A, Szabo E, Ungvari Z, Wolin MS, Groves JT and Szabo C (2003) Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation 107: 896-904.

25. Zucchi R and Danesi R (2003) Cardiac toxicity of antineoplastic anthracyclines. Curr Med Chem 3: 151-171.

26. Minotti G, Recalcati S, Mordente A, Liberi G, Calafiore A M, Mancuso C, Preziosi P and Cairo G (1998) The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron regulatory protein-1 in cytosolic fractions from human myocardium. FASEB J 12: 541-552.

27. Minotti G, Ronchi R, Salvatorelli E, Menna P and Cairo G (2001) Doxorubicin irreversibly inactivates Iron Regulatory Proteins 1 and 2 in cardiomyocytes : Evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy. Cancer Res 61: 8422-8428.

28. Kotamraju S, ChitambarCR, Kalivendi SV, Joseph J and Kalyanaraman B (2002) Transferrin receptor-dependent iron uptake is responsible for doxorubicin-mediated apoptosis in endothelial cells: role of oxidant-induced iron signaling in apoptosis. J Biol Chem 277: 17179-17187.

29. Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, Jones SE, Wadler S, Desai A, Vogel C, Speyer J, Mittelman A, Reddy S, Pendergrass K, Velez-Garcia E, Ewer MS, Bianchine JR and Gams RA (1997) Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15: 1318-1332.

30. Doroshow JH, Synold TW, Somlo G, Akman SA and Gajewski E (2001) Oxidative DNA base modifications in peripheral blood mononuclear cells of patients treated with high-dose infusional doxorubicin. Blood 97: 2839-2845.

31. Danesi R, Fogli S, Gennari A, Conte P and Del Tacca M (2002) Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs. Clin Pharmacokinet 41 : 431-444.

32. Meissner K, Sperker B, Karsten C, Zu Schwabedissen HM, Seeland U, Bohm M, Bien S, Dazert P, Kunert-Keil C, Vogelgesang S, Warzok R, Siegmund W, Cascorbi I, Wendt M and Kroemer HK (2002) Expression and localization of P-glycoprotein in human heart: effects of cardiomyopathy. J Histochem Cytochem 50: 1351-1356.

33. Reszka KJ, McCormick ML and Britigan BE (2001) Peroxidase- and nitrite-dependent metabolism of the anthracycline anticancer agents daunorubicin and doxorubicin. Biochemistry 40: 15349-15361.

34. Menna P, Salvatorelli E, Giampietro R, Liberi G, Teodori G, Calafiore AM and Minotti G (2002) Doxorubicin-dependent reduction of ferrylmyoglobin and inhibition of lipid peroxidation: implications for cardiotoxicity of anticancer anthracyclines. Chem Res Toxicol 15: 1179-1189.

35. Cartoni A, Menna P, Salvatorelli E, Braghiroli D, Giampietro R, Animati F, Urbani A, Del Boccio P and Minotti G (2004) Oxidative degradationof cardiotoxic anticancer anthracyclines to phthalic acids : Novel function for ferrylmyoglobin? J Biol Chem 279: 5088-5099.

Parole Chiave

ANTRACICLINE; DOXORUBICINA; DEGRADAZIONE OSSIDATIVA; ATTIVITA' ANTITUMORALE; CARDIOTOSSICITA'